<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MIDODRINE HYDROCHLORIDE</span><br/>(mid'o-dreen)<br/><span class="topboxtradename">ProAmatine<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha<sub>1</sub> agonist</span><br/><b>Prototype: </b>Methoxamine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Vasopressor and alpha<sub>1</sub> agonist. Activates the alpha-adrenergic receptors of the arteries and veins, resulting in increased vascular tone and elevation
         in blood pressure.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Affects standing, sitting, and supine systolic and diastolic blood pressures. Indicated by an increase in 1-min standing systolic
         BP and subjective feelings of clinical improvement.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of symptomatic orthostatic hypotension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe organic heart disease; acute kidney disease; urinary retention; pheochromocytoma; thyrotoxicosis; persistent and excessive
         supine hypertension.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, hepatic impairment; history of visual problems; diabetes with hypotension or visual disorders; pregnancy
         (category C), lactation. Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Orthostatic Hypotension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg t.i.d. during the daytime hours, dosed not less that 3 h apart with last dose at least 4 h before bedtime (max: 20 mg/dose)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give at bedtime or before napping (within 4 h of lying supine for any length of time)</li>
<li>Give with caution in persons with pretreatment, supine systolic BP <img src="../images/special/greaterorequal.gif"/>170 mm
            Hg.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Paresthesia,</span> chills, pain, facial flushing. <span class="typehead">CNS:</span> Confusion, nervousness, anxiety. <span class="typehead">CV:</span> <span class="speceff-common">Hypertension</span>. <span class="typehead">GI:</span> Dry mouth. <span class="typehead">Skin:</span> <span class="speceff-common">Pruritus, piloerection,</span> rash. <span class="typehead">Urogenital:</span> <span class="speceff-common">Dysuria, urinary retention, urinary frequency.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> may antagonize effects of <b>doxazosin,</b> <b>prazosin,</b> <b>terazosin;</b> may potentiate vasoconstrictive effects of <b>ephedrine,</b> <b>phenylephrine,</b> <b>phenylpropanolamine,</b> <b>pseudoephedrine;</b> may cause hypertensive crisis with <span class="classification">maois.</span>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> Midodrine 0.5 h; desglymidodrine 12 h. <span class="typehead">Metabolism:</span> Rapidly metabolized to desglymidodrine, the active metabolite. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> Midodrine 25 min, desglymidodrine 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Evaluate kidney and liver function prior to initiating therapy.</li>
<li>Monitor regularly supine and standing BP. Stop drug if supine BP increases excessively; determine acceptable parameters.</li>
<li>Monitor carefully effect of the drug in diabetics with orthostatic hypotension and those taking fludrocortisone acetate, which
            may increase intraocular pressure.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take last daily dose 4 h before bedtime.</li>
<li>Report immediately to physician sensations associated with supine hypertension (e.g., pounding in ears, headache, blurred
            vision, awareness of heart beating).
         </li>
<li>Discontinue drug and report to physician if S&amp;S of bradycardia develop (e.g., dizziness, pulse slowing, fainting).</li>
<li>Do not take allergy drugs, cold preparations, or diet pills without consulting physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>